Treatment Persistence and Factors Associated With Discontinuation in Real-World Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps. (PubMed, World J Otorhinolaryngol Head Neck Surg) - Oct 10, 2026 - "This retrospective single-center study included 95 adults with CRSwNP who initiated dupilumab (88.4%), mepolizumab, or omalizumab between 2021 and 2025. In this real-world cohort, discontinuation of the index biologic was driven mainly by adverse events and insufficient response. Early follow-up focused on tolerability and later review on disease control may be warranted."
Journal • Real-world evidence • Allergy • Chronic Rhinosinusitis With Nasal Polyps • Diabetes • Immunology • Metabolic Disorders • Musculoskeletal Pain • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis
|
|
Avraham Abergel; Eiman Abu Bandora; Forsan Jahashan; Hen Chaushu; Liyona Kampel; Narin Nard Carmel-Neiderman; Nidal Muhanna; Roni Vass; Yuval Presman
|